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Background. Long-term results of prospective randomized trials comparing triple immunosuppressive strategies
combining tacrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart
transplantation (HTX) are rarely published. Therefore, we collected long-term follow-up data of an intervention
cohort 10 years after randomization.
Methods. Ten-year follow-up data of 60 patients included in a prospective, randomized trial between 1998 and 2000
were analyzed as intention-to-treat (TAC-MMF n=30; CsA-MMF n=30). Baseline characteristics were well balanced.
Cardiac allograft vasculopathy (CAV) was graduated in accordance with the new ISHLT classification.
Results. Survival at 1, 5, and 10 years was 96.7%, 80.0%, and 66.7% for TAC-MMF and 90.0%, 83.3%, and 80.0% for
CsA-MMF (P=ns). Freedom from acute rejection (AR) was significantly higher in TAC-MMF versus CsA-MMF
(65.5% vs. 21.7%, log-rank 8.3, P=0.004). Freedom from ISHLTQCAV1 after 5 and 10 years was in TAC-MMF 64.0%
and 45.8%, and in CsA-MMF 36.0% (log-rank 3.0, P=0.085) and 8.0% (log-rank 9.0, P=0.003). No difference in long-
term results for freedom from coronary angioplasty or stenting, renal dysfunction, diabetes mellitus, CMV infection,
or malignancy was detected.
Conclusion. Cross-over effects because of treatment switch may result in impairment of significance between the
groups. The long-term analysis resulted in a significant difference in manifestation of CAV between the groups after
10 years. Less rejection in the TAC-group might have contributed to the lower incidence of CAV. Superior freedom
from AR and CAV in the TAC-MMF group did not result in better long-term survival.
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(Transplantation 2013;95: 629Y634)
S ince TAC was introduced into the clinic in 1989 (1Y5), itprogressively replaced CsA as calcineurin inhibitor (CNI)
after HTX (6). One of the first prospective, randomized
studies comparing CsA and TAC after HTX demonstrated
both CNI with the same efficacy and safety but with a trend to
less acute rejections for treatment with TAC (7). MMF, clin-
ically approved in 1995, was associated with a superior pre-
vention of acute rejection compared with Azathioprine (AZA)
in combination with CsA and corticosteroids (CS) in renal
transplant recipients (8). The improvement of 1-year mor-
tality and less acute rejection during the first year after HTX
was verified for MMF as a substitute for AZA (9). In 1998, we
designed a prospective randomized study to determine
whether TAC or CsA is the better partner for MMF after HTX
(10). The results 2 years after randomization presented both
CNI as adequate and effective partners with MMF to prevent
acute rejection in heart transplant recipients. In patients
treated with TAC-MMF, significantly fewer rejections were
observed. Patients treated with CsA-MMF needed signifi-
cantly higher doses of MMF to achieve the MPA target levels.
With respect to CAV, no significant difference between the
treatment groups was discovered; however, a more pro-
nounced intimal proliferation was detected in the CsA-MMF
group. Despite no differences in 2-year survival, we concluded
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that the short-term results of this randomized trial indicate
the superiority of TAC over CsA as better partner for MMF
after HTX (10).
Other prospective, randomized studies comparing
TAC and CsA (10Y20) also presented short- or mid-term
results based on follow-up periods from 6 months to 3 years
and in one case of 5 years (17).
The ISHLT registry detected a median survival of 11 years
for the entire cohort of adult and pediatric heart recipients
since initiation of the Registry in 1982 (6).
In view of the numerousness of heart recipients who
fortunately live more than 5 years after transplantation, the
question occurs whether the beneficial early results for TAC
observed in our prospective, randomized study could be
confirmed with longer follow-up and whether there will be
an impact on long-term outcome.
RESULTS
Baseline Characteristics and Patient Accounting
Patient demographic and baseline characteristics shown
in Table 1 were equally distributed across both treatment
groups. Because of death, the mean follow-up period was
9.1T3.3 years in TAC-MMF ITT and 8.8T4.0 years in CsA-
MMF ITT (P=0.712). There was no dropout of the random-
ized 60 patients but missing data in subcategories. Switch to
another immunosuppressive drug did not result in exclusion
from the ITT analysis. Because one patient of the TAC-group
moved to another transplantation center, only his survi-
val data were analyzed. Baseline coronary angiography de-
tected preexisting coronary artery disease in one patient of
each group.
Survival
Causes of death in the TAC-group were cancer (n=4,
3.4, 4.0, 4.3, and 5.7 years), acute rejection (n=2, 5.6, and
7.2 years; the second case because of noncompliance in
taking medications), systemic aspergillosis (n=1, 45 days),
sepsis (n=1, 2.6 years), ileus (n=1, 2.0 years), and multi-
organ failure (n=1, 8.2 years). Regarding the CsA group,
there was death because of cardiovascular complications
(n=3, 190 days, 2.9 and 3.7 years), systemic aspergillosis
(n=2, 10 and 12 days) and cancer (n=1, 6.2 years).
There was no statistical difference in long-term sur-
vival between the treatment groups (Fig. 1). Survival after
1 year was 93.3% (log-rank 1.1, P=0.301): in TAC-MMF
ITT 96.7% (n=29), and in CsA-MMF ITT 90.0% (n=27);
after 5 years, 81.7% (log-rank 0.1, P=0.800): in TAC-MMF
ITT 80.0% (n=24), and in CsA-MMF ITT 83.3% (n=25);
and after 10 years, 73.3% (log-rank 1.0, P=0.308): in TAC-
MMF ITT 66.7% (n=20), and in CsA-MMF ITT 80.0%
(n=24). Patients who had never been switched to another
immunosuppressive drug during treatment presented with in-
ferior survival without statistical significance (69.8%, P=0.369).
Acute Rejection
TAC-MMFYtreated patients had significantly lower
rates of rejection episodes than the CsA-MMFYtreated
patients as shown in Figure 2. Freedom from acute rejection
after 1 year was 47.5% in the study cohort with considerable
benefit of TAC-MMF (log-rank 6.1, P=0.013): in TAC-
MMF ITT 65.5% (n=19), and in CsA-MMF ITT 30.0%
(n=9); after 5 years, 44.1% (log-rank 8.3, P=0.004): in TAC-
MMF ITT 65.5% (n=19), and in CsA-MMF ITT 23.3%
(n=7); after 10 years 42.4% (log-rank 8.2, P=0.004): in
TAC-MMF ITT 65.5% (n=19), and in CsA-MMF ITT
21.7% (n=6). Mean freedom from acute rejection was in
TAC-MMF ITT 6.6 yT0.8 years, and in CsA-MMF ITT
2.9T0.8 years (95% CI 4.9Y8.3 and 1.4Y4.4 years).
Variance analysis on AR onset detected for MPA levels
during the first year a trend (P=0.051), and for ischemic time
TABLE 1. Patient demographic and baseline characteristics
Characteristics TAC-MMF ITT CsA-MMF ITT P
No. of patients 30 30 1.0
Mean follow-up time (yr) 9.1T3.3 8.8T4.0 0.712
Mean donor age (yr) 38T14 42T13 0.297
Mean recipient age (yr) 55T1 55T12 0.824
Donor sex (M/F) 16/14 18/12 0.795
Recipient sex (M/F) 26/4 24/6 0.731
Sex mismatch (recipient M/F) 10/0 7/1 0.347
Primary diagnosis
Dilated CMP 15 15 1.0
Ischemic CMP 15 15 1.0
CMV IgG Donor + 13 11 0.396
CMV IgG Recipient - 13 14 0.5
CMV Donor +/Recipient - 6 6 1.0
CMV prophylaxis postoperative 9 11 0.392
Mean ischemic time (h) 3.4T1.1 3.2T0.9 0.281
Operation duration (h) 4.7T0.9 4.4T1.0 0.480
ICU (d) 9.1T11.1 7.3T8.9 0.248
Ventilation postoperative (d) 2.5T2.9 3.2T5.4 0.627
meanTSD; CMP, cardiomyopathy; +, positive; -, negative.
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a significant impact (P=0.027). Adjusted for early MPA levels
and ischemic time, there was less AR in TAC-MMF ITT group
(OR 5.1, 95% CI 1.4Y18.3, P=0.013). Comparing patients
with and without AR within the same ITT, there were no
differences in MPA and TAC, respectively, CsA levels. Isolated
analysis of patients treated continuously with the randomized
immunosuppressive drug (n=43) showed comparable re-
sults with a freedom from AR of 46.5% 10 years after HTX
(log-rank 9.8, P=0.002): in TAC-MMF 68.0% (n=17), and
in CsA-MMF 16.7% (n=3).
Freedom From Treatment Failure
Treatment failure resulted in switch to another pri-
mary immunosuppressive drug. Four patients (13.8%) of
the TAC group were switched to another immunosuppres-
sive drug, three patients to sirolimus (SIR) because of renal
dysfunction (3.9, 4.4, and 9.4 years), and one patient to CsA
because of neuropathy (10 days). In the CsA group, 12 patients
(40.0%) were changed, two patients to SIR because of renal
dysfunction (1.9 and 3.2 years), five patients to TAC because
of AR (8, 13, and 67 days, and 1.1 and 1.3 years), one patient
to SIR because of AR but renal dysfunction (2.4 years), and
one patient in each group to SIR because of neuropathy
(4.9 years), to TAC because of gingival hyperplasia (1.5 years),
to everolimus (EVE) because of CAV (7.0 years) and to TAC
because of osteoporosis (2.0 years).
As shown in Figure 3, 1-year freedom from treatment
failure was 93.2% in the study cohort without difference
between ITT (log-rank 1.1, P=0.308): in TAC-MMF ITT
96.6% (n=28), and in CsA-MMF ITT 93.3% (n=27); and
after 5 years 79.7% (log-rank 3.7, P= 0.054): in TAC-MMF
ITT 89.7% (n=26), and in CsA-MMF ITT 70.0% (n=21);
and after 10 years, freedom from treatment failure was
72.9% with significantly less switch in TAC-MMF ITT (log-
rank 4.8, P=0.029): in TAC-MMF ITT 86.2% (n=25), and
in CsA-MMF ITT 60.0% (n=18).
Cardiac Allograft Vasculopathy
As shown in Figure 4, freedom from CAV
ISHLTQCAV1 onset was 96.4% in the TAC group vs. 88.5%
in the CsA group (log-rank 1.2, P=0.281) after 1 year, 64.0%
in the TAC group vs. 36.0% in the CsA group (log-rank 3.0,
P=0.085) after 5 years; and 45.8% in the TAC group vs.
8.0% in the CsA group (log-rank 9.0, P=0.003) after
10 years. The mean time until the first diagnosis of CAV
confirmed by coronary angiography was 7.8T0.8 years in the
TAC group and 4.6T0.7 years in the CsA group (95% CI
6.2Y9.4 years and 3.3Y5.9 years). Variance analysis on CAV
onset could not prove any impact of the common risk
parameters such as AR (P=0.566), donor age (P=0.124),
diabetes mellitus (P=0.805), LDL and cholesterol levels
(P=0.979 and P=0.355), systemic blood pressure (P=0.398),
and positive CMV titer (P=0.792). In contrast, CsA-MMF
was a significant risk factor in the multivariate analysis (OR
3.6; 95% CI 1.1Y11.4; P=0.031).
One patient of the CsA group underwent coronary
artery bypass grafting (7.89 years) because of severe CAV.
The patient has a simvastatine intolerance.
FIGURE 2. Freedom from acute rejection: Kaplan-Meier
analysis for 10 years after HTX (difference between the ITT
groups: log-rank 8.2, P=0.004).
FIGURE 1. Survival: Kaplan-Meier analysis for 10 years
after HTX (difference between the ITT groups: log-rank 1.0,
P=0.308).
FIGURE 3. Freedom from treatment failure: Kaplan-Meier
analysis for 10 years after HTX (difference between the ITT
groups: log-rank 4.8, P=0.029).
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Freedom from coronary stenting after follow-up was
87.5% (log-rank 0.2, P=0.693).
Regarding the continuous treatment groups without
switch to another immunosuppressive drug, there were 11
of TAC-treated patients and only three of CsA-treated
patients without CAV after 10 years of follow-up.
Treatment Dosages and Resulted Trough Level
Within the first 5 years and within the 10 years of
follow-up, administered TAC mean dosage of 4.1T2.0 mg/day
and 3.8T2.2 mg/day resulted in mean trough levels of
10.7T0.9 ng/mL and 9.9T1.0 ng/mL, and a CsA mean do-
sage of 200T41 mg/day and 184T45 mg/day resulted in
mean trough levels of 157T28 ng/mL and 132T39 ng/mL.
Only within the first 3 months of study duration, the
MPA levels (TAC-MMF ITT 3.1T1.0 vs CsA-MMF ITT
2.2T0.6 Kg/mL; P=0.003) were significantly lower in the
CsA-MMFYtreated patients, despite higher MMF doses.
Cytomegalovirus
There was no difference between the ITT groups about
preoperative CMV status and postoperative CMV prophy-
laxis (Table 1). Freedom from positive CMV titer was 58.6%
in the TAC group and 73.3% in the CsA group (log-rank
1.8, P=0.186). In two cases of the TAC-MMF ITT and three
cases of CsA-MMF ITT, there were severe CMV infections,
which required hospital admission. There were no causes of
death related to CMV infections.
Adverse Effects
Only at 5-year follow-up, there was a significantly
higher creatinine detected in the CsA group (1.60T1.21 mg/dL
in TAC-MMF ITT vs. 1.65T0.39 mg/dL in CsA-MMF
ITT, P=0.014), which cannot be reconfirmed at 10-year
follow-up (1.45T0.62 mg/dL in TAC-MMF ITT vs.
1.75T0.65 mg/dL in CsA-MMF ITT, P=0.120). After 5 and
10 years, creatinine levels of 2.0 mg/dL or greater were
found in 13.0% and 22.2% in the TAC group and in 28.0%
(P=0.180) and 41.7% (P=0.161) in the CsA group. Perma-
nent hemodialysis was inevitable in one patient of the CsA
group. Within the group of patients with drug application
as randomized over the whole time of follow-up, there seemed
to be a benefit for TAC-MMF over CsA-MMF in long-term
creatinine measurement (5-year follow-up: 1.39T0.61 mg/dL
vs. 1.74T0.36 mg/dL, P=0.005; and 10-year follow-up:
1.34T0.61 mg/dL vs. 1.91T0.63 mg/dL, P=0.012), despite
comparable baseline creatinine levels (1.46T0.91 mg/dL vs.
1.15T0.23 mg/dL, P=0.298).
Antidiabetic treatment (oral and/or insulin) was nec-
essary in 13.6% in the TAC group and in 16.7% in the CsA
group (P=0.551) at 5-year follow-up, and in 22.2% and in
18.2% (P=0.528) at 10-year follow-up.
During follow-up, 16 patients (27.1 %) developed
malignancy without statistical difference between the ITT
(P=0.252); 10 patients (34.5%) in TAC-MMF ITT and
6 patients (20.0%) in CsA-MMF ITT. Neoplasm of the skin
was found in five patients in the TAC group and three
patients in the CsA group, lymphoma in one case in each
group, and solid tumors in four patients in the TAC group
and two patients in the CsA group.
Immunosuppressant-associated side effects were as
follows: gastrointestinal disorders in the three cases in the
TAC group and one case in the CsA group, neuropathy in
two cases in the TAC group and three cases in the CsA
group, and osteoporosis in two cases in the TAC group and
four cases in the CsA group. In TAC-MMF ITT, one patient
experienced restless leg syndrome, and four patients in the
CsA group developed gingival hyperplasia.
DISCUSSION
The study (10) was primarily designed for the first
2 years after HTX. This long-term results are predicated on
routine examinations during follow-up period. Regarding
long-term survival, there was no significant difference be-
tween the treatment groups. Because of the small study co-
hort, the study may be underpowered to detect differences
in survival. Based on ITT analysis, it has to be considered
that the additive shorter patient-years for randomized
treatment with CsA versus TAC (190 versus 211 patient-
years) improved long-term outcome including long-term
survival by early switch to an individual beneficial primary
immunosuppressive drug.
The definition of AR as ISHLT (21) grade II (2R) and
higher or grade IB (1R) combined with clinical symptoms,
which necessitated steroid therapy is based on clinical
experiences in our transplantation center and was suitable to
other randomized studies (14, 16). The benefit of TAC over
CsA preventing AR after HTX was presented before (13, 14,
16, 18, 20). The ISHLT stated in the recommendations on
the principles of immunosuppressive regimens in heart
transplant recipients that the result of clinical trials suggest
that TAC-based regimens may be associated with lower re-
jection rates but not with superior survival compared with
CsA-based regimens (22). Our results emphasize this rec-
ommendation even with long-term results 10 years after
HTX. The lower MPA level during the first 3 months after
HTX in CsA-treated patients and the relatively high TAC
levels maintained throughout the first year (11.8T1.9 ng/mL)
may have contributed the significant difference in freedom
from AR between the ITT groups. Antibody-mediated rejec-
tion was not routinely tested at our center.
FIGURE 4. Freedom fromCAV: Kaplan-Meier analysis for
10 years after HTX (difference between the ITT groups: log-
rank 9.0, P=0.003).
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The development of CAV is deemed to be one of the
leading causes of posttransplant mortality particularly with
increasing follow-up time: between 1 and 3 years after HTX,
approximately 10% of deaths were shown to be associated
with CAV (6), and 5 years after HTX, 32% of deaths were
caused by CAV in addition with late-onset graft failure,
which could be related to undetected CAV (23, 24). Pro-
spective, randomized studies comparing TAC- and CsA-
based immunosuppressive regimens after HTX reported a
trend toward superior of preventing CAV for TAC (25, 26).
However, no significant difference between both CNI regi-
mens in angiographically detected CAV could be docu-
mented 5 years after HTX (17, 27). Reichenspurner (28)
characterized CAV as histologic manifestation of chronic
rejection after HTX, and he recognized the lack of long-term
data for incidence of CAV in TAC- and CsA-treated heart
recipients. In fact, and contrary to the current opinion be-
cause of absent evidence (27), our randomized study could
unmask a significantly better freedom from CAV in the
TAC-MMF ITT group but not until 10 years after HTX.
The duration and array of rejection episodes were
described as risk for CAV development (29, 30). Both were
not determined in this study. Stoica et al. (31) demonstrated
that acute moderate and severe cellular rejection had a cu-
mulative impact on CAV onset, whereas mild, untreated
rejection was not associated with CAV. This subdivision was
not considered in our study.
After 5 years of follow-up, there was a better creatinine
level in TAC-MMFYtreated patients, and almost twice the
number of patients in CsA-MMF group had creatinine levels
of 2.0 mg/dL or greater. Analysis of continuous randomized
treatment indicated that TAC-MMF treatment resulted in
lower creatinine levels, but a selection bias must be consid-
ered. Although the study cohort may be undersized to show
differences between the treatment groups, we disclose a
trend for TAC-MMF as beneficial therapy in renal function
like presented by Kobashigawa et al. (18).
CONCLUSION
In 2000, 23% of heart recipients achieved TAC; in
2009, its use increased to 73%, whereas the use of CsA has
decreased below 20% (6). There is no general preference
about CsA or TAC as CNI-based therapy after HTX in the
current ISHLT recommendations (22). Furthermore, no
evidence of different CAV rates between CsA- and TAC-
based therapies is documented by the ISHLT (27). We
conclude that the lack of evidence is based on insufficient
follow-up duration of randomized studies published so far.
Despite the limitation because of the small study cohort, this
study represents the first published prospective, rando-
mized study comparing TAC versus CsA in combination
with MMF over 10 years of follow-up including the new
ISHLT nomenclature for CAV (32). Our long-term analy-
sis resulted in a significant difference in manifestation of
CAV between TAC-MMFY and CsA-MMFYtreated patients.
However, cross-over effects because of treatment switch may
result in impairment of significance between the groups.
However, superior freedom from AR and CAV in the TAC
group did not result in better long-term survival.
MATERIALS AND METHODS
Patients
Complete 10-year follow-up data of 60 adult orthotopic heart transplant
recipients of a prospective, open-label, single-center, randomized trial were
analyzed. Between 1998 and 2000, all patients were 1:1 randomized to
treatment with TAC (n=30) or CsA (n=30) both in combination with
MMF as described previously (10). Exclusion criteria were age younger than
18 years, pregnancy or nursing, unwillingness or inability to use ade-
quate contraceptions during the study, cardiac retransplantation, previous
or multiorgan transplantation, human immunodeficiency virusYpositive
donor or recipient, serum creatinine greater than 2.5 mg/dL or elevated
transaminases greater than 1.5 times above reference value, or participation
in any other investigational drug study within 28 days of study entry. The
study protocol was approved by the local ethics committee and was con-
formed to the Declaration of Helsinki. All patients gave written informed
consent before inclusion.
University of Wisconsin solution was used as preservation medium.
Patients underwent routine follow-up examinations including drug level
monitoring, transvenous endomyocardial biopsy, echocardiography, and
coronary angiography according to center practice.
Study Medication and Drug Monitoring
Study medication (initial intravenously, subsequent oral) was administered
as described previously (10). Both CNIs and MMF were adjusted to target
levels (TAC: month 0Y6=13Y15 mg/mL, month 7Y12=10Y12 mg/mL, second
year=8Y10 mg/mL, third to fourth year=6Y8 mg/mL, fifth to tenth year=
4Y7 mg/mL; CsA: month 0Y6=200Y300 mg/mL, month 7Y24=150Y200 mg/mL,
third to tenth year=100Y150 mg/mL; MPA: month 0Y6=2.5Y4.0 Kg/mL, month
7 to tenth year: 1.5Y2.5 Kg/mL).
All patients received an intraoperative bolus of 500 mg methylprednis-
olone intravenously followed by 3125 mg within the initial 24 hours after
HTX. Prednisolone was weaned standardized without difference between
the treatment groups; the therapy was given for 6 months and withdrawn in
patients without repeated rejection episodes. None of the patients received
induction therapy. Because statins are beneficial for survival after HTX (33),
all patients received simvastatine routinely at a minimum dose of 5 mg/day
or in case of persistent hypercholesterolemia (total cholesterol, 9200 mg/dL
or low-density lipoprotein cholesterol 9140 mg/dL) at a maximum dosage
of 20 mg/day.
Acute Rejections
Transvenous endomyocardial biopsies were performed routinely after 1,
2, 3, 4, 6, 8, and 10 weeks; after 3, 4, 5, 6, 9, 12, and 24 months; and when
clinically indicated. Rejection was defined in adherence with the ISHLT (21)
as histologic grade II (2R) and higher or grade IB (1R) combined with
clinical symptoms, which necessitated steroid therapy or any treated rejec-
tion. According to the protocol in patients experiencing three rejection
episodes, a switch of the primary immunosuppressant was mandatory.
Cardiac Allograft Vasculopathy
Diagnosis of CAV was based on coronary angiography. There was a
baseline coronary angiography 1 month after transplantation for detecting
preexisting coronary artery disease. Afterward, the examinations were car-
ried out annually during the first years and increasingly infrequent when
clinically not indicated. CAV was graduated in accordance with the new
nomenclature for CAV published by the ISHLT in 2010 (32).
Statistical Analysis
Data are presented as ITT analysis unless otherwise indicated. Survival,
freedom from acute rejection, treatment switch, and CAV were calculated
using Kaplan-Meier analysis, and differences were assessed using log-rank
test. As nonparametric test, the Wilcoxon rank-sum test was used. The chi-
square test was performed to evaluate differences in adverse events. Influ-
ence of risk factors on AR and CAV onset were analyzed using logistic
regression analysis. Numerical data are listed as meanTstandard deviation
(SD). A PG0.05 was considered significant.
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